

Novartis India Limited Registered Office: Inspire BKC Part of 601 & 701 Bandra Kurla Complex Bandra (East) Mumbai – 400 051 Maharashtra, India Tel +91 22 50243000 Fax +91 22 50243010

Email: india.investors@novartis.com CIN No. L24200MH1947PLC006104

Website: www.novartis.in

December 31, 2020

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip code: 500672

- Sub.: 1. <u>Intimation of meeting of the Board of Directors of Novartis India Limited</u> ("the Company")
  - 2. Closure of Trading Window
- Ref.: 1. Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
  - 2. <u>Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015</u>

Dear Sir/ Madam,

Please be informed that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday, February 11, 2021, to *inter alia* consider the unaudited financial results of the Company for the quarter and nine-months ending on December 31, 2020 ("said results").

In this connection, further note that pursuant to the Company's Code of Conduct to regulate, monitor and report share trading by Insiders ["the Code"], the trading window for dealing in securities of the Company shall remain closed from Friday, January 1, 2021 to Saturday, February 13, 2021 (both days inclusive).

The same is being duly communicated to all the Designated Persons under the Code which is available on the Company's website i.e. <a href="https://www.novartis.in">www.novartis.in</a>.

This is for your information.

Thanking You.

Yours sincerely,

For Novartis India Limited

Trivikram Guda
Company Secretary &
Compliance Officer